Canadian radiopharmaceutical manufacturer Draxis Health reported record revenues of $10 million (U.S.) in the first quarter of 2002, up 18% from the $8.4 million booked in the first quarter last year. For the period (end-March 31), the Mississauga, Ontario-based vendor had net income of $783,000, compared with net income of $613,000 a year ago.
Strong results in the firm's radiopharmaceuticals business was driven primarily by increased product sales in the U.S., according to president and CEO Dr. Martin Barkin. These sales included fulfillment of order backlogs for the company's lyophilized diagnostic imaging products, he said.
By AuntMinnie.com staff writersMay 16, 2002
Related Reading
DraxImage brings production in-house, March 14, 2002
Draxis gets NRC approval for BrachySeed Pd-103, November 13, 2001
Draxis revenues climb, November 8, 2001
DraxImage to make radiotherapy capsules for Bracco, August 23, 2001
Draxis posts higher revenues in Q2, August 13, 2001
Copyright © 2002 AuntMinnie.com
